scholarly journals Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study

2018 ◽  
Vol 27 (2) ◽  
pp. 119-125 ◽  
Author(s):  
Rosa Rosania ◽  
Ulrike Von Arnim ◽  
Alexander Link ◽  
Mirjana Rajilic-Stojanovic ◽  
Caspar Franck ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Reports ◽  
Eradication Therapy ◽  
Case Control ◽  
Control Group ◽  
Serum Samples ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
H Pylori ◽  
Control Study

Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD.Methods: IBD outpatients with both Crohn´s disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded.Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p<0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16).Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD.Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.

Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis

2017 ◽  
Vol 44 (9) ◽  
pp. 1341-1346 ◽  
Author(s):  
Fabrizio Cantini ◽  
Laura Niccoli ◽  
Carlotta Nannini ◽  
Emanuele Cassarà ◽  
Olga Kaloudi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Anterior Uveitis ◽  
Skin Disease ◽  
Case Control Study ◽  
Case Control ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Control Study

Objective.To evaluate the frequency of dactylitis, enthesitis, and anterior uveitis (AU) in spondyloarthritis (SpA) associated with inflammatory bowel disease (IBD-SpA) compared with other SpA, and to assess the role of associated psoriasis in the occurrence of dactylitis and enthesitis.Methods.In a 12-month case-control study, the frequency of dactylitis and enthesitis in 29 patients with ulcerative colitis (UC) and 59 with Crohn disease (CD) who satisfied the Spondyloarthritis international Society criteria for axial or peripheral SpA was compared with 176 controls, including 97 (55.1%) with psoriatic arthritis (PsA), 47 (26.7%) with ankylosing spondylitis (AS), and 32 (18.2%) with nonradiographic axial SpA (nr-axSpA). The occurrence of these features in IBD-SpA with and without psoriasis was also evaluated.Results.Axial, peripheral, or mixed involvement was observed in 46 (52%), 29 (33%), and 13 (15%) patients, respectively; and 14/88 (16%) had psoriasis. Dactylitis was recorded in 4/88 patients (4.5%) with IBD-SpA and in 30 controls (17.4%; p = 0.008), enthesitis in 16 cases (18.1%) and in 78/176 controls (44.3%; p < 0.001), and AU in 3 patients (3.4%) with IBD-SpA and in 26 controls (14.7%; p = 0.01). No significant differences were found between patients with UC-SpA and those with CD-SpA. Dactylitis and enthesitis were significantly more common in patients with IBD-SpA who also had psoriasis compared to those without skin disease (p = 0.009 and 0.003, respectively).Conclusion.Dactylitis, enthesitis, and AU are significantly less frequent in IBD-SpA compared with other types of SpA. Given the frequent association of psoriasis and IBD, overlooking coexistent skin disease may lead to overestimating the frequency of these features.

scholarly journals The Role of Toxoplasma gondii Infection Among Multiple Sclerosis Patient Compared to Ordinary People in South of Iran: A Case-Control Study

2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Mahsa Rahnama ◽  
Qasem Asgari ◽  
Peiman Petramfar ◽  
Davod Tasa ◽  
Vahid Hemati ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Toxoplasma Gondii ◽  
Case Control Study ◽  
Case Control ◽  
Control Group ◽  
Ordinary People ◽  
Serum Samples ◽  
Significant Difference ◽  
Control Study

Background: Toxoplasmosis is a common parasitic disease, which leads to serious disease symptoms in immunocompromised hosts and infants. Recent epidemiologic surveys showed that microbial agents may be associated with some cases of multiple sclerosis (MS). Objectives: This case-control study aimed to examine the role of Toxoplasma gondii in MS by evaluating sero-frequency of anti-T. gondii IgG (ATXAb) antibody between patients with MS and ordinary people in Shiraz Province, south of Iran during 2016 - 2018. Methods: Serum samples obtained from MS patients (n = 130), and a group of age and gender-matched controls (n = 130) with the same socioeconomic status with the patients’ group were collected to evaluate the prevalence of T. gondii IgG antibodies (ATXAb). Moreover, the presence of the ATXAb antibody of the patients and controls was determined by the ELISA test. SPSS 20 software was used to perform the statistical analysis (SPSS, inc., Chicago, USA). Results: Out of 130 (35.4%) cases with MS and 130 (13.8%) controls, 46 and 18 subjects were seropositive for ATXAb, respectively. Based on the chi-square test, a significant difference was observed in terms of the positivity rates of ATXAb between the MS patient group and the control group (P = 0.001). The mean ± standard deviation ATXAb levels in controls and MS patients were found to be 61 ± 34 and 114 ± 47 IU/mL, respectively. Also, there were statistically significant differences between the levels of these two groups (P = 0.001). Conclusions: Given the relationship between toxoplasmosis and MS, it is possible that the prevalence of MS decreases by increasing hygiene and preventing toxoplasmosis.

Effect of Rural Living on the Development of the Inflammatory Bowel Diseases: A Nested Case-control Study

2011 ◽  
Vol 106 ◽  
pp. S474-S475 ◽  
Author(s):  
Alexandra Frolkis ◽  
James Hubbard ◽  
Jennifer Debruyn ◽  
Nathalie Jette ◽  
Cynthia Seow ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Case Control Study ◽  
Case Control ◽  
Rural Living ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Nested Case Control ◽  
Control Study

255 Aminosalicylates, Thiopurines and the Risk of Colorectal Cancer in Inflammatory Bowel Diseases: A Case-Control Study Nested in the CESAME Cohort

2010 ◽  
Vol 138 (5) ◽  
pp. S-47 ◽  
Author(s):  
Fabrice Carrat ◽  
Philippe Seksik ◽  
Anne-Marie Bouvier ◽  
Nicole Brousse ◽  
Franck Carbonnel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Diseases ◽  
Case Control Study ◽  
Case Control ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Control Study

scholarly journals Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

2020 ◽  
Author(s):  
Alexander Schwickert ◽  
Frédéric Chantraine ◽  
Loreen Ehrlich ◽  
Wolfgang Henrich ◽  
Mustafa Zelal Muallem ◽  
...  
Keyword(s):  
Case Control Study ◽  
Predictive Biomarker ◽  
Serum Levels ◽  
Case Control ◽  
Maternal Serum ◽  
Control Group ◽  
Serum Samples ◽  
Invasive Placenta ◽  
Control Study ◽  
Abnormally Invasive Placenta

Abstract The aim of this study was to test if maternal serum vascular endothelial growth factor (VEGF) or N-terminal pro B-type natriuretic peptide (NT-proBNP) predicts abnormally invasive placenta (AIP) better. Secondary objective was to test whether the serum levels of VEGF and NT-proBNP can predict the degree of invasion. In a multicenter case–control study design, gestational age-matched serum samples from pregnant women with AIP (n = 44) and uncomplicated pregnancies (n = 55) who had been enrolled at Charité – Universitätsmedizin Berlin, Germany and Centre Hospitalier Régional de la Citadelle in Liège, Belgium were analyzed. Maternal blood serum VEGF and NT-proBNP levels were immunoassayed from samples taken immediately before delivery (GA median: 35 weeks). Biomarker levels were compared between AIP and control group. The correlation of biomarker levels with the clinical AIP degree was assessed. The predictive biomarker ability was characterized through a multivariate regression model and receiver operating characteristic curves. Women with AIP had significantly lower maternal serum VEGF levels (AIP mean 285 pg/ml, 95% CI 248–322, vs. control: 391 pg/ml, 95% CI 356–426, p < 0.01) and higher NT-proBNP levels (AIP median 329 pg/ml, IQR 287–385, vs. control 295 pg/ml, IQR 273–356, p = 0.03). Maternal serum VEGF levels were able to predict AIP better (AUC = 0.729, 0.622–0.836, p < 0.001; VEGF + number of previous cesarean deliveries: AUC = 0.915, 0.853–0.977, p < 0.001). Maternal serum VEGF levels correlated inversely with the clinical AIP degree (r = − 0.32, p < 0.01). In short, maternal serum VEGF, more than NT-proBNP, can help in predicting AIP and hints at the degree of invasion.

scholarly journals Preclinical atherosclerosis in patients with inflammatory bowel diseases: a case-control study

2017 ◽  
Vol 5 (7) ◽  
pp. 158-158 ◽  
Author(s):  
Vincenzo Bruzzese ◽  
Giuseppe Palermo ◽  
Lorenzo Ridola ◽  
Roberto Lorenzetti ◽  
Cesare Hassan ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Case Control Study ◽  
Case Control ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Preclinical Atherosclerosis ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document